智通财经APP获悉，石药集团(01093)早盘涨超5%，截至发稿，涨2.19%，报9.81港元，成交4.46亿港 元。 消息面上，近日，石药集团及附属公司授权阿斯利康在全球范围内(除中国内地/港澳台)独家开发、生产 和商业化8个创新长效多肽药物项目(包括SYH2082及3个临床前阶段分子，并就另4个新增项目进行合 作)，阿斯利康将支付合计12亿美元预付款以及后续累计最高35亿/138亿美元的开发/销售里程碑款项。 其中巨石生物(新诺威控股子公司)有权收取首付款的35%以及根据实际情况后续收取相应开发/销售里程 碑款项以及特许权使用费。 中金认为，2025年公司已实现口服小分子GLP-1(1.2亿美元首付款)、阿斯利康战略合作(1.1亿美元预付 款)、伊利替康脂质体(1500万美元首付款)、ROR1 ADC(1500万美元首付款)的对外授权。公司研发管线 中还有EGFR ADC/SiRNA系列等进度领先的创新资产，该行期待有望持续实现对外授权落地和更多里 程碑收入确认。 ...

MNC押注超长效多肽药物，角逐减重与代谢大市场 2025年11月，辉瑞经过与诺和诺德激烈竞价最终以100亿美元对价实现对减肥药研发企业Metsera的收 购，Metsera基于其专有NuSH平台实现了MET-097(GLP-1，临床II期)的超长半衰期，使其具备每月注射 一次的药代动力学基础。而公司SYH2082是一款正推进至临床I期的每月一次注射长效GLP1R/GIP激动 剂，该行期待有更多优异疗效和安全性数据读出。 对外授权持续兑现，有望形成常态化收入 2025年公司已实现口服小分子GLP-1(1.2亿美元首付款)、阿斯利康战略合作(1.1亿美元预付款)、伊利替 康脂质体(1500万美元首付款)、ROR1ADC(1500万美元首付款)的对外授权。公司研发管线中还有EGFR ADC/SiRNA系列等进度领先的创新资产，该行期待有望持续实现对外授权落地和更多里程碑收入确 认。 中金发布研报称，维持石药集团(01093)"跑赢行业"评级，考虑对外授权持续兑现上调目标价9.1%到12 港元。该行维持公司25/26年盈利预测47.60亿元/53.53亿元，引入2027年56.95亿元预期。石药集团公告 与阿斯利康签 ...

智通财经APP获悉，中金发布研报称，维持石药集团(01093)"跑赢行业"评级，考虑对外授权持续兑现上 调目标价9.1%到12港元。该行维持公司25/26年盈利预测47.60亿元/53.53亿元，引入2027年56.95亿元预 期。石药集团公告与阿斯利康签订研发合作与授权协议。 中金主要观点如下： 2025年11月，辉瑞经过与诺和诺德激烈竞价最终以100亿美元对价实现对减肥药研发企业Metsera的收 购，Metsera基于其专有NuSH平台实现了MET-097(GLP-1，临床II期)的超长半衰期，使其具备每月注射 一次的药代动力学基础。而公司SYH2082是一款正推进至临床I期的每月一次注射长效GLP1R/GIP激动 剂，该行期待有更多优异疗效和安全性数据读出。 中国创新药授权出海再获里程碑式突破 对外授权持续兑现，有望形成常态化收入 根据公告，石药集团及附属公司授权阿斯利康在全球范围内(除中国内地/港澳台)独家开发、生产和商业 化8个创新长效多肽药物项目(包括SYH2082及3个临床前阶段分子，并就另4个新增项目进行合作)，阿 斯利康将支付合计12亿美元预付款以及后续累计最高35亿/138亿美元的开发/ ...

Group 1 - The article highlights the top short-selling ratios for various companies, with JD Health-R, Anta Sports-R, and Lenovo Group-R leading the list at 100.00%, 89.98%, and 89.87% respectively [1][2] - The top three companies by short-selling amount are CSPC Pharmaceutical Group at 1.268 billion, Zijin Mining Group at 1.031 billion, and Xiaomi Group-W at 1.014 billion [1][2] - The highest deviation values in short-selling are recorded for Kuaishou-WR at 36.02%, Xiaomi Group-WR at 30.00%, and Heptagon Pharmaceuticals-B at 26.77% [1][2] Group 2 - The top ten short-selling ratios include JD Health-R at 100.00%, Anta Sports-R at 89.98%, and Lenovo Group-R at 89.87%, with Kuaishou-WR and Xiaomi Group-WR also featuring prominently [2] - The top ten short-selling amounts show CSPC Pharmaceutical Group leading with 1.268 billion, followed by Zijin Mining Group and Xiaomi Group-W [2] - The top ten deviation values indicate significant short-selling activity, particularly for Kuaishou-WR and Xiaomi Group-WR, suggesting potential volatility [2]

证 券 研 究 报 告 行业周报 技术加持稳定原料药出口竞争力 医药行业周报 分析师：胡博新 SAC编号：S1050522120002 分析师：吴景欢 SAC编号：S1050523070004 医 药 行 业 观 点 2 诚信、专业、稳健、高效 请阅读最后一页重要免责声明 医 药 行 业 观 点 投资评级： 报告日期： 推荐 （ 维持 ） 2026年02月01日 1.技术加持稳定原料药出口竞争力，重视供给变量 根据医保商会数据，2025年中国医药保健品出口额1113.41亿美元，增长3.14%，其中西药原料出口额428.67亿美元，占西 药总出口的76.8%，同比微降0.27%。原料药出口能保持出口总量的相对稳定，是克服全球贸易变局和内部价格竞争内卷下 实现的，是中国原料药产业竞争力的体现。受关税贸易影响，2025年中国对美国医药出口下降了10.6%，而非美市场，欧 盟增长11.38%，新兴市场增长4.49%。展望2026年原料药贸易依然存在较多的不确定性，中国与印度之间原料药竞争合作 将进一步演绎。价格方面，价格竞争内卷是一方面，另一方面合成生物学等新技术加持，新工艺新产能的投产，单位成本 下降是重要一面。 ...

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [31] Core Insights - On January 30, 2023, the report highlights that the company has signed a strategic R&D cooperation and licensing agreement with AstraZeneca to develop innovative long-acting peptide drugs using its proprietary sustained-release drug delivery technology and peptide drug AI discovery platform [3] - AstraZeneca will gain global exclusive rights to the company's weight management product portfolio, which includes a clinical-ready project SYH2082 and three preclinical projects targeting obesity and weight-related issues [3] - The company is set to receive $1.2 billion in upfront payments, with potential milestone payments of up to $3.5 billion for R&D and up to $13.8 billion in sales milestone payments, along with a double-digit percentage royalty on annual net sales of the licensed products [3] Summary by Sections Industry Overview - The report emphasizes the increasing recognition of Chinese innovative pharmaceutical companies by international multinational corporations (MNCs), particularly through the recent collaboration with AstraZeneca [4] - The report also notes AstraZeneca's plan to invest $15 billion in China by 2030 to expand drug manufacturing and R&D, leveraging China's scientific capabilities and manufacturing strengths [4] Investment Strategy - The report suggests that the global competitiveness of Chinese innovative pharmaceutical companies is continuously improving, with a focus on potential treatment areas such as metabolic diseases, chronic diseases, and central nervous system disorders [5] - It recommends paying attention to emerging fields like small nucleic acid drugs, radioactive drugs, and CAR-T therapies, highlighting specific companies to watch [5] Market Performance - The pharmaceutical sector experienced a decline of 3.31% last week, ranking 20th among 28 industries, while the Hong Kong pharmaceutical sector fell by 2.98% [9][30] - The report indicates that the valuation of the pharmaceutical sector is at 32.45 times (TTM), with a premium of 15.83% compared to the overall A-shares [23]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.25 [1][4]. Core Insights - The company has announced a significant overseas deal for its long-acting peptide drug metabolism AI discovery platform, involving an upfront payment of USD 1.2 billion, potential R&D milestone payments of up to USD 3.5 billion, and sales milestone payments of up to USD 13.8 billion, along with a double-digit percentage royalty on net sales to AstraZeneca [1][2]. - This transaction is noted as the largest deal in the domestic pharmaceutical sector for the year, comparable to a previous major deal between 3SBio and Pfizer [1]. - The company is expected to benefit from the upfront payment, leading to a projected rapid year-on-year growth in net profit for 2026 [1]. - The long-acting metabolism platform is considered rare globally, with only Camurus having a similar platform, which enhances the company's competitive position in the overseas weight loss market [2]. Summary by Sections Transaction Details - The deal with AstraZeneca includes an upfront payment of USD 1.2 billion, potential R&D milestones of up to USD 3.5 billion, and sales milestones of up to USD 13.8 billion, along with a royalty on net sales [2]. - The platform includes core assets such as GIPR/GLP-1R and three preclinical weight loss pipelines, with plans for collaboration on four additional projects [2]. Platform Mechanism - The company possesses a leading liposome platform, and the fluid crystal technology allows for long-term release of active ingredients, enabling monthly or longer dosing [2]. Pipeline Potential - The company has a robust pipeline including EGFR ADC, which is expected to enter Phase III clinical trials both domestically and internationally, and other oncology and autoimmune therapies [3]. - The ADC pipeline targets HER3, B7H3, DLL3, and aims to address gaps in lung squamous carcinoma treatment [3]. Profit Forecast and Valuation - The projected net profits for the company from 2025 to 2027 are estimated at RMB 4.45 billion, RMB 8.46 billion, and RMB 5.60 billion respectively, with corresponding EPS of RMB 0.39, RMB 0.73, and RMB 0.49 [4][9]. - The company is assigned a PE ratio of 24 times for 2026, with a target price adjustment reflecting market conditions [4][11].

（GLP-1，临床II期）的超长半衰期，使其具备每月注射一次的药代动力学基础。而公司SYH2082 是一 款正推进至临床I期的每月一次注射长效GLP1R/GIP激动剂，我们期待有更多优异疗效和安全性数据读 出。 对外授权持续兑现，有望形成常态化收入。2025 年公司已实现口服小分子GLP-1（1.2 亿美元首付 款）、阿斯利康战略合作（1.1亿美元预付款）、伊利替康脂质体（1500 万美元首付款）、ROR1ADC （1500 万美元首付款）的对外授权。公司研发管线中还有EGFR ADC/SiRNA系列等进度领先的创新资 机构：中金公司 研究员：俞波/陈诗雨/张琎 公司近况 石药集团公告与阿斯利康签订研发合作与授权协议。 评论 中国创新药授权出海再获里程碑式突破。根据公告，石药集团及附属公司授权阿斯利康在全球范围内 （除中国内地/港澳台）独家开发、生产和商业化8 个创新长效多肽药物项目（包括SYH2082及3 个临床 前阶段分子，并就另4 个新增项目进行合作），阿斯利康将支付合计12 亿美元预付款以及后续累计最高 35 亿/138 亿美元的开发/销售里程碑款项。其中巨石生物（新诺威控股子公司）有权收取首付款的3 ...

Core Viewpoint - The article highlights the significant transactions in the Chinese innovative drug market, particularly focusing on weight loss and metabolic diseases, with a total potential value of approximately $25.8 billion from collaborations between Shijiazhuang Pharmaceutical Group and AstraZeneca, marking a pivotal moment for Chinese pharmaceutical companies in the global weight loss drug competition [5][8]. Group 1: Transaction Details - The collaboration includes a notable $18.5 billion deal for a long-acting weight management product, which sets a record for external licensing of innovative drugs from China [5]. - Shijiazhuang Pharmaceutical will receive an upfront payment of $1.2 billion, with potential milestone payments of up to $3.5 billion for research and $13.8 billion for sales, along with revenue-sharing agreements [6]. - The partnership extends beyond specific molecules to include Shijiazhuang's sustained-release delivery technology platform and AI drug discovery platform, indicating a long-term strategic collaboration rather than a one-time transaction [6]. Group 2: Market Trends and Competitive Landscape - The focus on long-acting formulations in weight loss drugs is driven by market realities, as competition in weight loss efficacy approaches a ceiling, making dosing frequency and patient adherence critical for commercial success [7]. - Shijiazhuang's sustained-release technology aligns with the industry's shift towards longer dosing intervals, with monthly or longer intervals seen as essential for next-generation weight loss drugs [7]. - The integration of AI-driven drug discovery platforms has proven to be a valuable asset, as demonstrated by previous collaborations with AstraZeneca, which have resulted in high-value agreements for various projects [8]. Group 3: Implications for the Industry - The $25.8 billion in transactions reflects a profound shift in the competitive logic of the global weight loss drug market, moving from simple weight loss metrics to a comprehensive competition involving dosing methods, treatment cycle management, and platform innovation capabilities [8][9]. - Shijiazhuang's multi-layered approach in the weight loss and metabolic field, including long-acting GLP-1 and dual-target projects, oral small molecules, and AI-driven innovations, enhances its bargaining power in collaborations [8]. - As long-acting products enter clinical validation, the competitive threshold in the weight loss drug market will rise, making it strategically important for global pharmaceutical companies to secure partnerships with capable platform providers [9].

Core Viewpoint - The strategic collaboration between CSPC Pharmaceutical Group and AstraZeneca, valued at up to $18.5 billion, was met with unexpected market skepticism, leading to a significant drop in stock prices for both companies involved [2][4][7]. Group 1: Strategic Collaboration Details - CSPC Pharmaceutical Group announced a strategic partnership with AstraZeneca to co-develop innovative long-acting peptide drugs based on CSPC's drug delivery technology and AI discovery platform [3][4]. - The agreement includes a $1.2 billion upfront payment, up to $3.5 billion in research milestone payments, and $13.8 billion in sales milestone payments, along with a double-digit revenue share based on annual net sales [4][5]. - This deal surpasses the previous record of $11.4 billion set by Innovent Biologics and Takeda in 2025, marking a new high for outbound licensing in China's biopharmaceutical sector [4]. Group 2: Market Reaction and Concerns - Following the announcement, CSPC's stock fell by 9.82% to HKD 9.64 per share, while its closely related company, New Horizon Health, saw a drop of 15.72% [2][7]. - Analysts suggest that the market's negative reaction stems from concerns over the details of the deal and the companies' fundamentals, indicating that the perceived benefits may not align with the actual risks involved [7]. - The milestone payments are contingent on successful clinical trials and market performance, raising questions about the viability of CSPC's projects in a competitive landscape [7][8]. Group 3: Product and Competitive Landscape - The core asset in this collaboration is SYH2082, a long-acting weight management drug currently in Phase I clinical trials, targeting GLP-1R and GIPR receptors [8][9]. - The competitive landscape for GLP-1 drugs is intensifying, with major players like Eli Lilly and domestic companies rapidly advancing their own dual-target and multi-target drugs [9][10]. - CSPC's late entry into the clinical phase with SYH2082 presents challenges in efficacy differentiation and safety optimization, which will be critical for its future competitiveness [10]. Group 4: Financial Context and Implications - CSPC's decision to pursue this significant licensing deal comes at a time when its financial performance is under pressure, with a reported revenue decline of 12.32% year-on-year for the first three quarters of 2025 [11]. - New Horizon Health stands to benefit from the upfront payment, which will help alleviate its cash flow issues as it anticipates a significant net loss in 2025 due to high R&D expenditures [12].